Estelle Marrer-Berger

Estelle Marrer-Berger has over 20 years of experience in the pharmaceutical industry. Estelle began their career in 1999 as a PhD student at Hoffmann-La Roche. In 2002, they became a Post-Doctoral Fellow at Basilea Pharmaceutica Ltd. In 2004, they moved to Novartis as a Biomarker Expert in Oncology. In 2007, they joined Novartis Pharma AG as a Project Toxicologist and Science and Portfolio Manager and later as a Senior Investigator in Discovery and Investigative Safety. In 2017, they became a Toxicology Project Leader at Roche. Most recently, in 2022, they were appointed Chief Development Officer (CDO) at 3T Biosciences.

Estelle Marrer-Berger obtained their PhD in Microbiology and Immunology from Universit\u00e9 Louis Pasteur (Strasbourg I) between 1999 and 2002.